Jyong Biotech Ltd. Sample Contracts
INDEMNIFICATION AGREEMENTIndemnification Agreement • August 17th, 2023 • Jyong Biotech Ltd. • Pharmaceutical preparations • New York
This Indemnification Agreement (this “Agreement”) is entered into as of by and between Jyong Biotech Ltd., a Cayman Islands company (the “Company”), and the undersigned, a director and/or an officer of the Company (“Indemnitee”), as applicable.
EMPLOYMENT AGREEMENTEmployment Agreement • August 17th, 2023 • Jyong Biotech Ltd. • Pharmaceutical preparations • New York
This EMPLOYMENT AGREEMENT (the “Agreement”), is entered into as of ______ (the “Effective Date”), by and between Jyong Biotech Ltd., a company limited by shares in Cayman Islands (the “Company”), and ______ , an individual (the “Executive”) (individually, each a “Party” and collectively, the “Parties”). Except with respect to the direct employment of the Executive by the Company, the term “Company” as used herein with respect to all obligations of the Executive hereunder shall be deemed to include the Company and all of its subsidiaries and affiliated entities (collectively, the “Group”).
DIRECTOR AGREEMENTDirector Agreement • August 17th, 2023 • Jyong Biotech Ltd. • Pharmaceutical preparations • New York
This DIRECTOR AGREEMENT (the “Agreement”), is entered into as of _______ (the “Effective Date”), by and between Jyong Biotech Ltd., incorporated under the laws of the Cayman Islands (the “Company”), and [*], an individual (the “Director”) (individually, each a “Party” and collectively, the “Parties”). The term “Company” as used herein with respect to all obligations of the Director hereunder shall be deemed to include the Company and all of its subsidiaries and affiliated entities (collectively, the “Group”).
Jyong Biotech Ltd. UNDERWRITING AGREEMENTUnderwriting Agreement • February 6th, 2025 • Jyong Biotech Ltd. • Pharmaceutical preparations • New York
The undersigned, Jyong Biotech Ltd., a Cayman Islands exempted company (the “Company”), hereby confirms its agreement (this “Agreement”) with Joseph Stone Capital, LLC (the “Representative”) to issue and sell to the underwriters named on Schedule A hereto (each, an “Underwriter” and collectively, “Underwriters”) an aggregate of [ ] ordinary shares, par value $0.00001 per share (the “Ordinary Shares”), of the Company (the “Firm Shares”). The Company also agrees to issue and sell to the Underwriters not more than an additional [ ] Ordinary Shares (the “Option Shares”), if and to the extent that the Underwriters shall have determined to exercise the right to purchase such shares of Option Shares granted to the Underwriters. The Firm Shares and the Option Shares are hereinafter collectively referred to as the “Securities.” The offering and sale of securities contemplated by this Agreement is referred to herein as the “Offering.”
Jyong Biotech Ltd. UNDERWRITING AGREEMENTUnderwriting Agreement • June 20th, 2025 • Jyong Biotech Ltd. • Pharmaceutical preparations • New York
The undersigned, Jyong Biotech Ltd., a Cayman Islands exempted company (the “Company”), hereby confirms its agreement (this “Agreement”) with Joseph Stone Capital, LLC (the “Representative”) to issue and sell to the underwriters named on Schedule A hereto (each, an “Underwriter” and collectively, “Underwriters”) an aggregate of 2,666,667 ordinary shares, par value $0.00001 per share (the “Ordinary Shares”), of the Company (the “Firm Shares”). The Company also agrees to issue and sell to the Underwriters not more than an additional 400,000 Ordinary Shares (the “Option Shares”), if and to the extent that the Underwriters shall have determined to exercise the right to purchase such shares of Option Shares granted to the Underwriters. The Firm Shares and the Option Shares are hereinafter collectively referred to as the “Securities.” The offering and sale of securities contemplated by this Agreement is referred to herein as the “Offering.”
Jyong Biotech Ltd. Supplementary Agreement of the “Share Transaction Agreement”Supplementary Agreement of the Share Transaction Agreement • August 17th, 2023 • Jyong Biotech Ltd. • Pharmaceutical preparations
The Supplementary Agreement of the Share Transaction Agreement (the “Supplementary Agreement” was entered into by the parties below on 2 July 2019:
Credit AgreementCredit Agreement • May 8th, 2024 • Jyong Biotech Ltd. • Pharmaceutical preparations
The person signing the agreement (hereinafter referred to as the contracting party) with Taiwan Cooperative Bank Co., Ltd. (including the head office and its branches, hereinafter referred to as your bank) agree to abide by the following terms in all business transactions with the bank.
Trading Agreement of Jyong Biotech Ltd. Service SharesTrading Agreement • August 17th, 2023 • Jyong Biotech Ltd. • Pharmaceutical preparations
(The Party A, Party B, Party C, Party D and Party E in this Agreement are called the “all parties”; each party is called “one party” depending on the texting requirements)
Management Committee of Aggregating Area of Taizhou Bay Circulating Economic Productions Industries (Gaoxin Zone and Luxin Resort Zone) Chuang-Yao Biotech Pharmaceutical Co., Ltd. Jianyong Biotechnology Herbal Medicine Project Investment Cooperation...Investment Cooperation Agreement • August 17th, 2023 • Jyong Biotech Ltd. • Pharmaceutical preparations
Party A: Management Committee of Aggregating Area of Taizhou Bay Circulating Economic Productions Industries (Gaoxin Zone and Luxin Resort Zone)
Project Cooperation Framework AgreementProject Cooperation Framework Agreement • August 17th, 2023 • Jyong Biotech Ltd. • Pharmaceutical preparations
Health Ever Bio-Tech Co., Ltd. was established in 2002 with a paid-in capital of NT$730 million; its operating headquarters are located in Taiwan (Taipei City, Bali District of New Taipei City and Yilan County). It is the only company in the world to develop new botanical medicines for men with enlarged prostate. At present, the company has 4 varieties of new medicines in clinical stage. MCS-2 is a new botanical medicine for the treatment of prostatic hypertrophy independently developed by the company. It has completed Phase III clinical trials in humans by the US FDA and Taiwan Medicine Administration, which has successfully completed the unblinding procedures of US FDA in April 2017 and Taiwan Medicine Administration in May 2016; and completed the US Pre-NDA (Pre-Medicine License Application Meeting) in the first quarter of 2018; it will submit a medicine license application to the United States in the first quarter of 2019. The new medicine is expected to be launched in 2022. In mai